

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-251)	RILDINADSTROCEL
PRONUNCIATION	ril" din ad' stroe sel
THERAPEUTIC CLAIM	Treatment of Acute respiratory distress syndrome (ARDS)

DESCRIPTION

COVI- MSC (previously identified as PSC-04) is an allogeneic culture-expanded adipose-derived mesenchymal stem cells derived from a disease-screened donor's adipose tissue collected via liposuction and which undergoes tissue processing and manufacturing of the cell product under Good Manufacturing Processes. The product undergoes various pathogen assessments and procedures to verify final product sterility including sterility by direct filtration, mycoplasma by polymerase chain reaction, and endotoxin evaluation. A maximum of 5 passages from the master cell bank (MCB) are used for culture expansion to maintain MSC viability. The MSC pellet is a white to cream color.

TRADEMARK	COVI-MSC
SPONSOR	Sorrento Therapeutics, Inc.
CODE DESIGNATION	PSC-04, MSC
UNII	3ME9TTI5QB
WHO NUMBER	12412

scs